Pharm Chapter 9

Front 1

BONE MARROW SUPPRESSION RESULTS IN INFECTIONS

Back 1

TRUE

Front 2

CYCLOSPORINE FREQUENTLY CAUSES GINGIVAL ENLARGEMENT.

Back 2

TRUE

Front 3

ALTERED TASTE IS OFTEN NOTED IN CANCER PATIENTS RECEIVING CHEMOTHERAPY.

Back 3

TRUE

Front 4

WHICH OF THE FOLLOWING EVENTS OCCURS WHEN THERE IS DAMAGE TO THE SALIVARY GLANDS DURING CANCER THERAPY?

Back 4

XEROSTOMIA

Front 5

WHICH OF THE FOLLOWING EVENTS OCCURS WHEN THERE IS A LOW WHITE BLOOD CELL COUNT?

Back 5

INFECTION

Front 6

WHICH OF THE FOLLOWING EVENTS OCCURS WHEN THERE IS A LOW RED BLOOD CELL COUNT?

Back 6

ANEMIA

Front 7

WHICH OF THE FOLLOWING EVENTS OCCURS WHEN THERE IS A LOW PLATELET COUNT?

Back 7

BLEEDING

Front 8

WHICH OF THE FOLLOWING WHITE BLOOD CELL LEVELS IS THE MINIMUM FOR DENTALL TREATMENT?

Back 8

<1000/MM3

Front 9

WHICH OF THE FOLLOWING AGENTS IS RECOMMENDED FOR CANCER PATIENTS WITH XEROSTOMIA?

Back 9

FLUORIDE RINSE

Front 10

WHICH OF THE FOLLOWING PROCEDURES SHOULD BE PERFORMED BEFORE A PATIENT STARTS ANTICANCER TERAPY?

Back 10

EXTRACTION OF HOPELESS TEETH, PERIODONTAL SURGERY, ENDODONTIC THERAPY

Front 11

WHICH OF THE FOLLOWING IS HELPFUL IN REDUCING ORAL BACTERIAL LEVELS?

Back 11

CHLORHEXIDINE

Front 12

ORAL CANDIDIASIS OCCURS IN PATIENTS TAKING ANTICANCER DRUGS DUE TO A DECREASE IN

Back 12

WHITE BLOOD CELLS

Front 13

A PATIENT WITH METASTASIS INTO BONE MAY BE TAKING WHICH OF THE FOLLOWING DRUGS TO PREVENT FURTHER SPREAD?

Back 13

BISPHOSPHONATES

Front 14

BECAUSE OF LAKE OF SPECIFICITY, MOST ANTINEOPLASTIC DRUGS COMMONLY PRODUCE?

Back 14

BONE MARROW SUPPRESSION

Front 15

BRUISING IS A COMMON SIDE EFFECT OF CHEMOTHERAPY CAUSED BY A DEFICIENCY OF

Back 15

PLATELETS

Front 16

WHICHO OF THE FOLLOWING WOULD NOT BE OBSERVED WITH TREATMENT USING ANTINEOPLASTICS?

Back 16

HYPERCHOLESTEROLEMIA

Front 17

ALTERED TASTE

Back 17

DYSGEUSIA

Front 18

DEATH/NECROSIS OF BONE

Back 18

OSTEONECROSIS

Front 19

DECREASED PLATELET COUNT (CAUSES INCREASED BLEEDING)

Back 19

THROMBOCYTOPENIA

Front 20

LOW WHITE BLOOD CELL COUNT

Back 20

NEUTROPENIA

Front 21

TOXIC EFFECT ON CELLS

Back 21

CYTOTOXICITY

Front 22

DECREASED RED BLOOD CELL COUNT

Back 22

ANEMIA

Front 23

THE TWO MOST COMMON ADVERSE SIDE EFFECTS FROM ANTINEOPLASTICS ARE:

Back 23

NAUSEA, VOMITING

Front 24

3 ANATOMIC LOCATIONS OF RAPIDLY- DIVING CELLS IN THE HUMAN BODY THAT ARE MOST AFFECTED BY ANTINEOPLASTIC DRUGS:

Back 24

HAIR FOLLICLES, BONE MARROW, GI TRACT

Front 25

METHOTREXATE CAN BE PRESCRIBED NOT ONLY FOR CERTAIN TYPES OF CANCERS BUT ALSO FOR

Back 25

RHEUMATOID ARTHRITIS

Front 26

WHAT IS THE HALF-LIFE OF ALENDRONATE (FOSAMAX)?

Back 26

10 YEARS OR MORE

Front 27

WHAT IS THE DENTAL COMPLICATION ASSOCIATED WITH BISPHOSPHONATES AND DENTAL PROCEDURES SUCH AS EXTRACTION AND PERIODONTAL SURGERY?

Back 27

OSTEONECROSIS OF THE JAW

Front 28

3 CONDITIONS TREATED WITH BISPHONATES?

Back 28

1. OSTEOPOROSIS
2. OSTEOLYTIC TUMORS
3.PAGET'S DISEASE

Front 29

STATE THE MECHANISM OF ACTION OF BISPHOSPHONATES:

Back 29

INHIBITING BONE RESORPTION BY DECREASING ACTION OF OSTEOCLASTS

Front 30

3 SIGNS/SYMPTOMS OF OSTEONECROSIS OF THE JAW

Back 30

1. EXPOSED BONE THAT HASNT HEALED
2. PAIN, INFLAMMATION
3.MOBILITY OF TEETH

Front 31

WHAT IS THE SUFFIX FOR BISPHOSPHONATE DRUGS?

Back 31

DRONATES

Front 32

TREAT VARIOUS TYPES OF CANCERS OR NEOPLASMS (ABNORMALLY GROWING CELLS) THAT CANNONT BE TREATED BY SURGERY OR ARE USED IN CONJUNCTION WITH SURGERY AND RADIATION THERAPY.

Back 32

ANTINEOPLASTIC DRUGS

Front 33

ANTINEOPLASTICS, THE MOST TOXIC DRUGS IN USE TODAY

Back 33

ACT BY KILLING CANCER CELLS THROUGH DAMAGING CELL DNA OR INTERFERING WITH DNA SYNTHESIS

Front 34

MOST DRUGS WHILE KILLING CANCER CELLS ALSO AFFECT

Back 34

NORMAL CELLS

Front 35

OTHER TOXIC EFFECTS FROM ANTINEOPLASTIC DRUGS IS

Back 35

1.BONE MARROW SUPPRESSION
2. DECREASE IN NEUTROPHILS OR WHITE BLOOD CELLS. PRE DISPOSES THEM TO SERIOUS INFECTION
3.THROMBOCYTOPENIA (DECREASE IN PLATELETS) LEADING TO SERIOUS BLEEDING PROBLEMS.

Front 36

A MAJOR CASUE OF CANCER TREATMENT FAILURE IS

Back 36

DRUG RESISTANCE

Front 37

NORMAL NEUTROPHIL COUNT=

Back 37

4,300 - 10,800/MM3

Front 38

NORMAL THROMBOCYTE (PLATELET) COUNT=

Back 38

150,000-350,000/MM3

Front 39

COMPLICATIONS OF THE ORAL CAVITY OCCUR IN ABOUT 40% OF PATIENTS TREATED WITH CHEMOTHERAPY AND _______ PATIENTS RECEIVING RADIATION.

Back 39

ALL

Front 40

INCREASED INCIDENCE OF CANDIDIASIS AND DENTAL/ ROOT CARIES

Back 40

XEROSTOMIA

Front 41

NEUTRAL SODIUM FLUORIDE RINSE SUCH AS PREVIDENT RINSE TO PREVENT

Back 41

CARIES

Front 42

IS COMMON RESULTING FROM AN OVERGROWTH OF FUNGI BECAUSE OF REDUCED WHITE BLOOD CELL COUNT.

Back 42

ORAL CANDIDIASIS
-IT MAY BE MORE IMPORTANT TO PREVENT RATHER THAN TREAT ORAL CANDIDIASIS

Front 43

ALTERATIONS IN TASTE ARE COMMONLY SEEN IN THE CANCER PATIENT CALLED

Back 43

DYSGEUSIA

Front 44

GINGIVAL ENLARGEMENT

Back 44

CYCLOSPORINE

Front 45

PATIENTS TAKING IMMUNOSUPPRESSANTS WILL MOST LIKELY DEVELOP

Back 45

HYPERTENSION

Front 46

BACTERIAL INFECTIONS ARE SEEN WITH ____ _____ SUPPRESSION

Back 46

BONE MARROW

Front 47

IMMUNOSUPPRESSANT DRUGS ARE USED IN ORGAN TRANSPLANT PATIENTS TO PREVENT

Back 47

REJECTION OF THE ORGAN

Front 48

ANTIBOTICS MAY BE NECESSARY WHEN WHITE BLOOD CELL COUNTS FALL BELOW

Back 48

1,500 MM3

Front 49

WHICH OF THE FOLLOWING TREATMENTS SHOULD BE STARTED FOR PATIENTS WHO COMPLAIN OF ORAL MUCOSITIS?

Back 49

RINSE WITH VISCOUS LIDOCAINE

Front 50

WHICH OF THE FOLLOWING DRUGS MAY CAUSE GINGIVAL ENLARGEMENT?

Back 50

CYCLOSPORINE

Front 51

WHICH OF THE FOLLOWING SIGNS SHOULD BE MONITORED IN THE DENTAL OFFICE IN A PATIENT TAKING CYCLOSPORINE?

Back 51

BLOOD PRESSURE

Front 52

A PATIENT TAKING ZOLEDRONATE FOR PAIN FROM MULTIPLE MYELOMA (A CANCER). WHICH OF THE FOLLOWING CONDITIONS CAN DEVELOP AFTER PERIODONTAL DEBRIDEMENT?

Back 52

OSTEONECROSIS